12.19.13
A clinical study on Capros (patented Phyllanthus emblica extract, commonly known as Indian gooseberry), published online in Phytomedicine, showed that Capros caused a significant decrease in platelet aggregation. In a 10 day study, Capros (500 mg twice daily) reduced platelet aggregation by over 36%, compared to 50% by Clopidrogel (75 mg once daily) and 51% by Aspirin (75 mg once daily). However, when Caproswas taken in conjunction with Clopidrogel or Aspirin, the inhibition of platelet aggregation increased only marginally to 53% and 56%, respectively. Bleeding and clotting times were not significantly affected by Caproswhen used alone or in conjunction with either Clopidrogel or Aspirin.
There were also no adverse effects or bleeding events reported. An area of concern is the inhibition of platelet aggregation greater than 50%, which is strongly correlated with bleeding events. Capros alone produced only 27% and 36% inhibition of platelet aggregation in single dose and multiple dose studies respectively, compared to 47% and 50% for Clopidrogel and 46% and 51% for Aspirin.
For more information: www.natreoninc.com
There were also no adverse effects or bleeding events reported. An area of concern is the inhibition of platelet aggregation greater than 50%, which is strongly correlated with bleeding events. Capros alone produced only 27% and 36% inhibition of platelet aggregation in single dose and multiple dose studies respectively, compared to 47% and 50% for Clopidrogel and 46% and 51% for Aspirin.
For more information: www.natreoninc.com
